http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014113967-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 2012-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014113967-A |
| titleOfInvention | COMBINED THERAPY OF MULTIPLE SCLEROSIS BY INTERFERON AND ANDROGRAPHOLIDES |
| abstract | 1. A method of treating demyelinating diseases in a human patient, comprising administering to the patient interferon, improved in that it comprises administering to the patient a compound of formula I: wherein R is selected from the series consisting of hydrogen, alkyl and hydroxyl, R is selected from the series consisting of hydroxyalkyl and alkyl-OL, where L is a carbohydrate group, R is selected from the series consisting of hydrogen and hydroxyl, X is selected from the series consisting of C (= CH), CH (OH) and spirooxyran-2, Z is selected from the series consisting of from CH, CH (OH) and C (= O), R is selected from the series consisting of optionally substituted L-alkyl and L-alkenyl, where L is an optionally substituted 3-furanyl or 3-fur-3-enyl group, or a pharmaceutically acceptable salt, ester, ether or proto-drug thereof. 2. The method of claim 1, wherein the demyelinating disease is multiple sclerosis. The method of claim 1, wherein the interferon is selected from the series consisting of purified naturally-occurring interferon, synthetic interferon, and recombinant interferon. The method of claim 3, wherein the interferon is interferon beta. The method of claim 1, wherein R1 is methyl. A method according to claim 1, wherein R is selected from the series consisting of hydroxymethyl and CH-O-Glc, where Glc is a glycoside-forming glucose residue. The method of claim 1, wherein R is selected from the series consisting of 3- (3-furanyl) propyl, 3- (3-furanyl) prop-1-enyl, 3- (3-furanyl) prop-2- enyl, 3- (3-fur-3-enyl) propyl or 3- (3-fur-3-enyl) prop-1-enyl, where 3-furanyl or 3-fur-3-enyl groups may additionally be replaced. 8. The method according to claim 1, wherein R is selected from the series consisting of where R is selected from the series consisting of hydrogen and hydroxyl, R and R are independently selected from the series consisting of hydrogen |
| priorityDate | 2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.